Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 4, 2011Critical Care Medicine

Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center

View Full Paper
Ask AI
Bookmark
Share

Authors

AFAntoine FroissartMBM. BuffetAVAgnès Veyradier

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Froissart et al. (2011) studied this question.

synapsesocial.com/papers/6a9f5fa64e5f4deab168ffddhttps://doi.org/10.1097/ccm.0b013e31822e9d66
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Rituximab: Expanding Role in Therapy for Lymphomas and Autoimmune Diseases2004 · 215 citations
  2. 2Rituximab Can Be Combined With Daily Plasma Exchange to Achieve Effective B-Cell Depletion and Clinical Improvement in Acute Autoimmune TTP2006 · 54 citations
  3. 3Structure of von Willebrand Factor-cleaving Protease (ADAMTS13), a Metalloprotease Involved in Thrombotic Thrombocytopenic Purpura2001 · 848 citations
  4. 4Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura2008 · 579 citations
  5. 5Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion1996 · 792 citations